Nils R. Winter,Julian Blanke,Ramona Leenings,Jan Ernsting,Lukas Fisch,Kelvin Sarink,Carlotta Barkhau,Daniel Emden,Katharina Thiel,Kira Flinkenflügel,Alexandra Winter,Janik Goltermann,Susanne Meinert,Katharina Dohm,Jonathan Repple,Marius Gruber,Elisabeth J. Leehr,Nils Opel,Dominik Grotegerd,Ronny Redlich,Robert Nitsch,Jochen Bauer,Walter Heindel,Joachim Gross,Benjamin Risse,Till F. M. Andlauer,Andreas J. Forstner,Markus M. Nöthen,Marcella Rietschel,Stefan G. Hofmann,Julia-Katharina Pfarr,Lea Teutenberg,Paula Usemann,Florian Thomas-Odenthal,Adrian Wroblewski,Katharina Brosch,Frederike Stein,Andreas Jansen,Hamidreza Jamalabadi,Nina Alexander,Benjamin Straube,Igor Nenadić,Tilo Kircher,Udo Dannlowski,Tim Hahn

Abstract:Importance Biological psychiatry aims to understand mental disorders in terms of altered neurobiological pathways. However, for one of the most prevalent and disabling mental disorders, major depressive disorder (MDD), no informative biomarkers have been identified. Objective To evaluate whether machine learning (ML) can identify a multivariate biomarker for MDD. Design, Setting, and Participants This study used data from the Marburg-Münster Affective Disorders Cohort Study, a case-control clinical neuroimaging study. Patients with acute or lifetime MDD and healthy controls aged 18 to 65 years were recruited from primary care and the general population in Münster and Marburg, Germany, from September 11, 2014, to September 26, 2018. The Münster Neuroimaging Cohort (MNC) was used as an independent partial replication sample. Data were analyzed from April 2022 to June 2023. Exposure Patients with MDD and healthy controls. Main Outcome and Measure Diagnostic classification accuracy was quantified on an individual level using an extensive ML-based multivariate approach across a comprehensive range of neuroimaging modalities, including structural and functional magnetic resonance imaging and diffusion tensor imaging as well as a polygenic risk score for depression. Results Of 1801 included participants, 1162 (64.5%) were female, and the mean (SD) age was 36.1 (13.1) years. There were a total of 856 patients with MDD (47.5%) and 945 healthy controls (52.5%). The MNC replication sample included 1198 individuals (362 with MDD [30.1%] and 836 healthy controls [69.9%]). Training and testing a total of 4 million ML models, mean (SD) accuracies for diagnostic classification ranged between 48.1% (3.6%) and 62.0% (4.8%). Integrating neuroimaging modalities and stratifying individuals based on age, sex, treatment, or remission status does not enhance model performance. Findings were replicated within study sites and also observed in structural magnetic resonance imaging within MNC. Under simulated conditions of perfect reliability, performance did not significantly improve. Analyzing model errors suggests that symptom severity could be a potential focus for identifying MDD subgroups. Conclusion and Relevance Despite the improved predictive capability of multivariate compared with univariate neuroimaging markers, no informative individual-level MDD biomarker—even under extensive ML optimization in a large sample of diagnosed patients—could be identified.

A Machine Learning Analysis of Big Metabolomics Data for Classifying Depression: Model Development and Validation

Using Data-Driven Algorithms with Large-Scale Plasma Proteomic Data to Discover Novel Biomarkers for Diagnosing Depression

Finding the best predictive model for hypertensive depression in older adults based on machine learning and metabolomics research

Identification of Diagnostic Markers for Major Depressive Disorder Using Machine Learning Methods

Evaluation of metabolomics-based urinary biomarker models for recognizing major depression disorder and bipolar disorder

Metabolomics on depression: A comparison of clinical and animal research

Subphenotyping Depression Using Machine Learning and Electronic Health Records

Identifying Depression Through Machine Learning Analysis of Omics Data: Scoping Review

Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder

Decoding depression: a comprehensive multi-cohort exploration of blood DNA methylation using machine learning and deep learning approaches

Development of a differential treatment selection model for depression on consolidated and transformed clinical trial datasets

Machine learning in major depression: From classification to treatment outcome prediction

Using an Interpretable Amino Acid-Based Machine Learning Method to Enhance the Diagnosis of Major Depressive Disorder

A Systematic Evaluation of Machine Learning–Based Biomarkers for Major Depressive Disorder

Evaluation of nutritional status and clinical depression classification using an explainable machine learning method

Identification and Validation of Urinary Metabolite Biomarkers for Major Depressive Disorder

Study on plasma metabolomics profiling of depression in Chinese community-dwelling older adults based on untargeted LC/GC‒MS

Graph convolutional network with attention mechanism improve major depressive depression diagnosis based on plasma biomarkers and neuroimaging data

Development of Machine-Learning-driven Signatures for Diagnosing and Monitoring Therapeutic Response in Major Depressive Disorder Using Integrated Immune Cell Profiles and Plasma Cytokines

Detection study of bipolar depression through the application of model-based algorithm in terms of clinical feature and peripheral biomarkers

Optimizing multi-domain hematologic biomarkers and clinical features for the differential diagnosis of unipolar depression and bipolar depression